Is edaravone harmful? (A placebo is not a control)

Area of Science:

• Neurology
• Clinical Trials
• Pharmacology

Background:

• Edaravone is administered via long-term daily intravenous infusions for Amyotrophic Lateral Sclerosis (ALS).
• The potential risks associated with intravenous infusions were not adequately considered in the design or analysis of pivotal efficacy studies for edaravone in ALS.
• This oversight may impact the accurate assessment of edaravone's true therapeutic benefit.

Discussion:

• Reappraisal of the pivotal Study 19 suggests that infusion-related risks cannot be dismissed.
• The efficacy of edaravone may be overestimated due to confounding factors from the administration method.
• Observed differences between edaravone and placebo might not solely reflect the ALS disease process.

Key Insights:

• In placebo-controlled trials where conditions may be harmful, treatment must be superior to placebo and better than no intervention.
• Study 19 indicated edaravone performed better than placebo, but both arms likely fared worse than receiving no intervention.
• This suggests a potential overestimation of edaravone's efficacy and raises concerns about its current delivery method.

Outlook:

• Further investigation is needed to disentangle the effects of edaravone from infusion-related harms.
• Alternative delivery methods or formulations of edaravone should be explored to mitigate risks.
• Current evidence suggests edaravone, as presently administered, may be both ineffective and potentially harmful for ALS patients.